DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Joubert syndrome — screening already-approved drugs against its 31-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJoubert syndrome maps to a 31-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for joubert syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphodiesterase 6D (PDE6D) — PDE6D is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4JV8 · 1.45 Å · ligand (6R)-6-(pyridin-2-yl)-5,6-dihydrobenzimidazo[1,2-c]quinazoline (1M1). Experimental structure, not a prediction.
What the evidence adds up to
Joubert syndrome is a rare autosomal recessive disorder diagnosed by neuroimaging hallmarks: the molar tooth sign and a batwing shaped fourth ventricle. Clinically it presents with neonatal breathing dysregulation, hypotonia, ataxia, nystagmus, developmental delay, and intellectual disability. Multiorgan involvement can include retinal dystrophy, cystic kidney disease, and liver fibrosis. A 2014 case report of a 12-year-old patient with classical complaints and abnormal facies was diagnosed on computed tomography; the authors note that extreme caution is needed when administering drugs because these patients are prone to respiratory depression. A 2011 case report states that treatment is symptomatic and supportive, and that infant stimulation and physical, occupational, and speech therapy may benefit some patients.
A 2002 series of four children from a group of 11 Joubert syndrome patients (36.36%) described a favourable evolution. Ages ranged from 25 months to 12 years. Three of the four had comprehensive language appropriate for their age; two began talking at 19 and 20 months. Three exhibited normal language, while one communicated only by gestures at the last study. All four walked without help. Two patients assessed with the Raven scale showed borderline intellectual quotient; both were self-sufficient in daily cleanliness and feeding. One patient could read, write, and perform mathematical calculations. The authors conclude that Joubert syndrome is clinically and genetically heterogeneous, and that a careful neuropsychological evaluation is necessary before giving a prognosis.
A 2023 case report identified novel compound heterozygous variants in the TMEM67 gene as the cause of Joubert syndrome in one patient. No treatment or outcome data beyond the genetic finding are provided in that abstract.
What is still missing are any controlled trials of pharmacological interventions, any drug specifically tested for Joubert syndrome, and any validated biomarkers to stratify patients by prognosis. The literature remains limited to small case series and genetic reports, with no randomised evidence to guide drug repurposing or to predict which patients will follow a favourable course.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Polish Journal of Radiology · 2014 · 6 citations · open access
Joubert Syndrome: Imaging Features and Illustration of a Case
AbstractBACKGROUND: Joubert Syndrome (JS) is a rare autosomal recessive disorder characterised clinically by neonatal breathing dysregulation, developmental delay, intellectual disability, hypotonia, ataxia, nystagmus. CASE REPORT: We present another case of this uncommon syndrome in a 12 years old patient presenting with classical complaints of developmental delay, intellectual impairment, weakness in both lower limbs, ataxia and abnormal facies and diagnosed on Computed Tomography. CONCLUSIONS: Joubert Syndrome should be ruled out in all patients presenting with hypotonia, ataxia, nystagmus, breathing abnormalities and developmental delay. Its neuroimaging hallmarks include molar tooth sign and batwing shaped fourth ventricle. As JS is associated with multiorgan involvement, these patients should enter a diagnostic protocol to assess systemic abnormalities. Extreme caution should be taken while administering drugs in these patients as they are prone to respiratory depression.
Journal of Nepal Paediatric Society · 2011 · 3 citations · open access
Joubert's Syndrome: A Case Report
AbstractJoubert's syndrome is an autosomal recessive congenital disorder having characteristic clinical features like hypotonia, ataxia, developmental delay and many neurological problems. Other variable features include retinal dystrophy, cystic kidney disease liver fibrosis etc. Treatment for Joubert syndrome is symptomatic and supportive. Infant stimulation and physical, occupational, and speech therapy may benefit some patients. Infants with abnormal breathing patterns should be monitored. Key words: Joubert's syndrome; molar tooth sign; cerebellar peduncles; vermis hypoplasia. DOI: 10.3126/jnps.v31i2.3908 J Nep Paedtr Soc 2010;31(2):141-142
Síndrome de Joubert. Presentación de cuatro casos con evolución favorable
AbstractOBJECTIVES: To present 4 patients with Joubert syndrome who had a favourable evolution as well as to show that many cases have better prognosis than it is usually though. CASE REPORT: Anamnesis, image and psychological studies of 4 children with Joubert syndrome, who had been seen in the Pediatric Neurology Service of the University Hospital La Paz of Madrid. RESULTS: Four of our 11 patients with Joubert syndrome (36.36%) presented a favourable evolution. Their age ranged between 25 months old and 12 years old. The comprehensive language corresponded to their ages in 3 patients. Two patients began to talk at 19 and 20 months respectively. Three children exhibited a normal language and 1 only communicated by gestures at the time of the last clinical study. All the four children walked without help. The mental level was calculated by the Raven scale in 2 cases and they showed a borderline intellectual quotient (IQ). Both patients were self sufficient in their daily cleanliness and feeding. A patient was able to read, to write and to make mathematical calculi. CONCLUSIONS: The Joubert syndrome is a heterogeneous disease from the clinic and genetics points of view, as well as in the evolution. Because of that, an attentive neuropsychological evaluation is necessary before giving the prognosis of the children.
Sage Journals Data · 2023 · 0 citations · open access
sj-pdf-1-imr-10.1177_03000605231206294 - Supplemental material for A case of Joubert syndrome caused by novel compound heterozygous variants in the <i>TMEM67</i> gene
AbstractSupplemental material, sj-pdf-1-imr-10.1177_03000605231206294 for A case of Joubert syndrome caused by novel compound heterozygous variants in the <i>TMEM67</i> gene by Anastasiya Aleksandrovna Kozina, Guria Kurbanovna Kanaeva, Natalia Vladimirovna Baryshnikova, Anna Yurievna Ilinskaya, Anna Alexandrovna Kim, Anastasia Vladimirovna Erofeeva, Nadezhda Andreevna Pogodina, Jamilya Payzutdinova Gadzhiyeva, Ekaterina Ivanovna Surkova and Valery Vladimirovich Ilinsky in Journal of International Medical Research
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
